Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (2580)	7/24/2000 6:07:26 PM
From: DanZ	Read Replies (2) \| Respond to of 5582

It took me all of five minutes to find dozens of links on the Internet related to the active ingredients in Zicam Allergy Relief. The two links that follow contain an excellent description of the active ingredients and clinical studies that have been done on them previously. It is obvious that the combination of ingredients in Zicam Allergy Relief have been proven effective and aren't crushed tea leaves. Do you really expect anyone to take you seriously with such ludicrous and obviously biased comments? I was wrong about the same combination of ingredients being available in other products, but I wasn't wrong that the gel matrix makes the product unique. Like I said, it comes down to marketing, and it looks like the other products are only distributed through natural health stores. Zicam Allergy Relief is available at many of the same 50,000 mainstream stores where Zicam Cold Remedy is sold, so it would appear that Gel Tech has better distribution than the other products. Regarding your comments in message 2581: Early in 1999, I predicted that GUMM would trade to 32 by the end of 1999. This prediction came true about five weeks late (big deal), in early February. I don't recall giving a price target of 100 for this year, but I do think that the stock could reach 60 this year if the prophylactic clinical study comes back positive and Gum Tech forms a partnership with a large pharmaceutical company to market Zicam. Unless you have a crystal ball that allows you to see years into the future, you don't know if Gum Tech will always lose money. In fact, logic says you are wrong. Do you think that they will always lose money on gum with Swedish Match as their partner for non tobacco nicotine products? Gum Tech only needs to sell between $2.5 million and $3.0 million in gum quarterly to break even. Do you really think that Swedish Match would form a joint venture for the sale of non-tobacco nicotine products and contribute $10 million in start up capital if they thought their quarterly sales would only be $3 million? You will be proven wrong in time and I think you are the one smoking tea leaves. _____ Link 1: BHI is introducing a new remedy administered as a nasal spray, for the treatment of hayfever. It contains Luffa operculata, Galphimia glauca, Histaminum, and Sulfur; all remedies with a proven track record in the treatment of allergies in general and hayfever in particular. Galphimia glauca is a plant that grows wild in Mexico whose provings were done in 'Germany in the 1960's. The main clinical symptoms associated with the proving were a "hypersecretion from the nasal and ocular mucous membranes, sneezing, edema of the eyelids. (O.A. Julian): all symptoms classically associated with hayfever and allergic rhinitis. Hayfever has been successfully treated with Galphimia glauca in Europe for years. There are some clinical trials that have been conducted with this remedy (Wiesenauer M., Gaus W. Double-blind trial comparing the effectiveness of the homeopathic preparation Galphimia potentisation D6, Galphimia dilution 10-4 and placebo on pollinosis. Arznelmittelforschung 1985; 35:1745-7.) Luffa operculata is a plant from South America with provings done in 1962. Acute and chronic inflammations of the nasal mucous membranes were one of the keynotes. Histamine had provings done in 1950 and hayfever and other allergic conditions figure prominently in its symptom picture. Sulphur, the greatest of the homeopathic polycrests, has hayfever and allergic rhinitis present in the many symptoms that it is capable of treating. shanahazee.com Link 2: WEISER and colleagues, Institut fur Antihomotoxische Medizin und Grundregulationsforschung, Baden-Baden, Mannhein, Germany compared the efficacy and tolerance of a homoeopathic nasal spray for hay fever (seasonal allergic rhinitis) with conventional intranasal cromolyn sodium therapy. Methods: 146 patients with hay fever symptoms were recruited into the randomised, double-blind trial of 42 days. The homoeopathic remedy (Luffa comp. –Heel trade mark Nasal Spray), 0.14 ml per application, 4 times per day consisted of a fixed combination comprised of Luffa operculata, Galphimia glauca, histamine and sulfur. Quality of life, as measured using the Rhinoconjunctivitis quality of Life Questionnaire (RQLQ) was the principal outcome measure. The trial medication tolerance was measured using global assessment, rhinoscopy, recording of adverse events and the use of vital and laboratory parameters. Results: The treatment showed quick and lasting effects. This effect was independent from the medication applied and produced an almost complete remission of hay fever symptoms. RQLQ global scores changed significantly during the course of the treatment, demonstrating therapeutic equivalence between the 2 forms of treatment. There were no adverse systemic effects, although local adverse events appeared in 3 patients. Conclusions: The homoeopathic nasal spray is as efficient and well tolerated as conventional therapy with cromolyn sodium for the treatment of hay fever. Weiser M et al. A randomized equivalence trial comparing the efficacy and safety of Luffa comp .-Heel nasal spray with cromolyn sodium spray in the treatment of seasonal allergic rhinitis. Forschende Komplementaermedizin 6(3): 142-8 Jun 1999. positivehealth.com